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ABSTRACT In this article, the Group Chairs and early career members of the European Respiratory
Society (ERS) Paediatric Assembly highlight some of the most interesting findings in the field of
paediatrics which were presented at the 2018 international ERS Congress.
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The 2018 international European Respiratory Society (ERS) Congress in Paris, France reflected the ERS’s
commitment to support the continuing professional and academic development of the 1500 members of
the Paediatric Assembly (Assembly 7). Members of the Assembly presented over 350 scientific abstracts in
addition to a postgraduate course on cystic fibrosis (CF), two meet the expert sessions (on bronchoscopic
evaluation of recurrent pneumonia and primary ciliary dyskinesia (PCD)), a skills workshop on
endoscopy, four scientific symposia, one year in review session, the paediatric grand round and a
state-of-the-art session. A new, and very successful, format was the “lung on fire” session, where a panel of
paediatric experts were put to the test by clinical cases provided by the audience. In previous years, the
senior officers of the Assembly have reviewed the highlights of the Congress [1, 2]. In contrast, this year’s
review of the Congress was a partnership between our Early Career Members (i.e. members aged
<40 years) and the Assembly Group Chairs. Each pair report what they personally found to be the most
interesting findings of the Congress, inspired by data presented in both abstracts and spoken sessions.
Prematurity and lung disease
New insights into prematurity and lung disease ranged from interventions following premature delivery to
optimise lung aeration, through early biomarkers and predictors of future chronic lung disease, to the later
pulmonary consequences of prematurity.
BIZZOTTO et al. [3] randomised lambs delivered prematurely at 128 days (approximately equivalent to
28 weeks gestation in humans) to receive two sustained inflations or continuous positive airway pressure
immediately after delivery. All lambs were subsequently maintained on noninvasive positive pressure
ventilation. Forced oscillation at 5 Hz was used to assess lung aeration. Whilst the lambs that received
sustained inflations had greater and more homogenous lung aeration, differences were only significant for
the first 3 hours of life. This may help to explain why although sustained inflations may reduce the need
for ventilation, benefits do not appear to be sustained in the long term [4, 5].
Another animal study of the effects of preterm birth by DAHL et al. [6], addressed the long-term
respiratory consequences of preterm birth. In this model, lambs were ventilated for 3–6 days and then
weaned from support. Compared to control lambs, airway reactance was increased in the first 2 months of
life. At the equivalent age of ∼6 years in humans, the preterm lambs had significantly increased airway
smooth muscle thickness compared to controls, despite normal reactance and lung mechanics at that time.
If oxidative stress contributes to the development of bronchopulmonary dysplasia (BPD), then antioxidant
gene variants may influence susceptibility [7]. PAVLINOVA et al. [8] investigated allelic polymorphisms of
manganese superoxide dismutase (MnSOD) by isolating genomic DNA from infants with and without
BPD. The researchers found that substitution of cytosine for thymine at position 16 on the MnSOD gene
(resulting in substitution of valine for alanine) was present in 90% of infants with BPD compared to only
32% without BPD (p=0.006), whereas two other mutations showed no such increased susceptibility. This
underlines the hypothesis that antioxidant gene variants are involved in the multifactorial aetiology of BPD.
Two abstracts addressed methods to predict subsequent development of BPD in “at risk” infants. ZANNIN
et al. [9] used forced oscillation in 68 non-intubated infants born at <32 weeks. Respiratory system
reactance (Xrs) was associated with duration of respiratory support, and the best multivariate model
predicting BPD incorporated gestational age and Xrs (β= −0.62, 95% CI −1.07– −0.17; p=0.008). A
late-breaking abstract from KINDT-DUNJKO et al. [10] used machine learning to identify different protein
signatures that might predict BPD development. In this study, plasma samples were taken at day 1–7 from
infants who went on to develop mild BPD compared to those who developed moderate or severe BPD.
Proteins implicated in disease severity of later BPD were those involved in inflammatory signalling, cardiac
strain and coagulation activation.
One goal of early identification of infants at risk of a higher burden of respiratory disease is to target
potential future therapies. A potential therapeutic target was reported by GALLACHER et al. [11] who showed
that extracellular apoptosis-associated speck-like protein containing a caspase activation domain was
instrumental in interleukin (IL)-6 and IL-8 production from respiratory cell analogues, and that this may
represent a potential therapeutic target to prevent chronic lung disease.
There is evidence to suggest that azithromycin has the potential to reduce the development of BPD, but
this approach may only have a significant benefit in infants colonised with ureaplasma [12, 13]. VISCARDI
et al. [14] presented the results of a double-blind placebo-controlled trial of intravenous azithromycin
(20 mg·kg−1) in the prevention of severe respiratory morbidity in infants born at 24–28+6 weeks. Infants
with tracheal aspirates positive for ureaplasma had higher mortality (29% versus 10%, p<0.01), and higher
rates of BPD (67% versus 50%, p<0.01). By contrast, tracheal aspirate ureaplasma positive infants that
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received azithromycin had lower rates of death or severe respiratory morbidity at 1 year than the placebo
group (three (33%) out of nine versus six (86%) out of seven, p=0.036).
Even longer term outcomes of prematurity were addressed by HARRIS et al. [15] who found that
self-reported exercise (measured as how much time per week children exercised) correlated poorly with
performance on exercise testing in adolescents who had been born prematurely. Poorer lung clearance
index (LCI; a measure of ventilatory inhomogeneity) was predictive of poorer performance, but other lung
function tests were not correlated with exercise distance, suggesting that lung function abnormalities may
not always be associated with functional impairment.
Molecular and cellular determinants of the developing lung
The thematic poster session “Molecular and cellular determinants of the developing lung” was the first
official ERS session for the new Group 7.08: Lung and Airway Developmental Biology, which was formed
in 2018. This session featured 12 posters covering the newest studies on normal lung development,
hyperoxia-induced neonatal lung injury, asthma/airway hyperreactivity and developmental origins of
chronic lung disease.
Using single cell RNA sequencing on human fetal lungs, DANOPOULOS et al. [16] showed that various
distinct mesenchymal lineages, including endothelial cells, pericytes, smooth muscle cells and fibroblasts,
are already specified in pseudoglandular (11.5 weeks) lungs. A study by WANG et al. [17] focused on the
maturation of the airway smooth muscle (ASM) layer during late gestation to the first year in life in human
lungs. Using stereological techniques, they found that the ASM layer thickens with a concomitant reduction
in ASM cell density as a result of hypertrophy. In turn, MIURA et al. [18] presented data implicating a role
for epithelial phosphatase and tensin homolog deleted on chromosome 10 in controlling programmed cell
senescence and cell fate choices during lung development in mice, by regulating the NF-κB-Notch pathway.
Studies aiming at elucidating processes involved in hyperoxia-induced injury of the newborn lung, as a
model for BPD in preterm infants, were particularly well represented in this session. In a study by COLLINS
et al. [19], which was selected from the 2018 Lung Science Conference in Estoril, Portugal, CD146+ lung
mesenchymal stromal cells (L-MSCs) isolated from hyperoxia-injured rat lungs displayed an impaired
angiogenic supportive capacity and altered gene expression profile, suggesting an active role for L-MSCs in
BPD pathogenesis [20]. HIRANI et al. [21] presented data suggesting an injurious effect of macrophages on
lung epithelial cells following hyperoxia exposure, mediated by IL-6. Loss of IL-6 on the other hand protected
against hyperoxia-injury in neonatal mice. HIRANI et al. [22] also presented data on the downregulation of
Krüppel-like factor 4 (Klf4) in myofibroblasts following hyperoxia exposure in neonatal mice, linking this to
myofibroblast activation and potential contribution to BPD pathogenesis. MOHR et al. [23] also identified a
role for Klf4 in alveolar epithelial type II cells, which was diminished after hyperoxia exposure in neonatal
mice. Potential therapeutic targets for the treatment of BPD were also presented. SYED et al. [24] showed that
an agonistic antibody aimed at the triggering receptor expressed on myeloid cells-1, which is upregulated as
an adaptive response to hyperoxia in neonatal mouse and human lungs, could alleviate pulmonary alveolar
injury and inflammation by downregulating receptor-interacting protein kinase 3-mediated cell death. Using
a hyperoxia-induced newborn guinea pig model of experimental BPD, KATOVICH et al. [25] reported that
inhalation therapy with N-acetylcysteine could prevent alveolar hypoplasia through normalisation of the
redox balance and an improved elastase/A1-AT ratio.
Exposures to the developing lung can not only lead to effects that are directly apparent, but can also
predispose for chronic lung disease that manifests at a later age. The usefulness of zebrafish as a potential
novel animal model for chronic lung disease in this regard was presented in a study by LJUJICH et al. [26],
showing a correlation between the effects of nicotine exposure on mammals and zebrafish. In turn, PINCUS
et al. [27] looked at maternal house dust mite exposure in mice as a model for asthma, finding that this
increases sensory airway innervation and airway hyperreactivity in offspring. Lastly, presenting a late
breaking abstract, KOVACH et al. [28] obtained serum from dog-allergen sensitised children, and found that
while IL-26 and IL-17A concentrations were increased in this group compared to those without allergen
sensitisation, IL-26 also correlated with improved asthma control. This would support the view that
exposure to pets indeed has a protective effect in the early origins of asthma.
Paediatric asthma: prevention, diagnosis and treatment
Presentations at the ERS Congress covered the wide spectrum of asthma, including prevention, diagnosis
and treatment. Exploring the intriguing association between pre-natal maternal psychological stress [29],
LIU et al. [30] performed a population-based study on Danish children born between 1997 and 2008,
examining the relationship between maternal pre-natal stress and the risk of offspring asthma. Whilst
private life stress (e.g. bereavement and illness) did not influence the risk, maternal exposure to lower job
demand and with low job control increased the risk.
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Another emerging protective factor for asthma is the interaction between exposure to bacterial products
and microbiota. One source of early life microbial exposure is via breast milk. HÄMYNEN et al. [31]
explored the connection between microbiota in breast milk and asthma by 6 years of age. Breast milk
samples were collected from mothers from the PASTURE birth cohort (Finland, France, Germany and
Switzerland). Differences in bacterial strains were found in different countries; gram-negative bacteria
showed a significant association with asthma in Germany and Switzerland. The respired environment is
another source of bacterial product exposure. Previous reports that asthma is less prevalent in children
exposed to a wider range of microbes (e.g. living on farms) [32] suggests a role for either inhalation or
ingestion of bacterial products. PEKKANEN et al. [33] studied the differences in house dust microbiota
composition between farm and non-farm homes in Finland. Floor dust bacteria and fungus were
sequenced at the age of 2 months, while the outcome was defined as asthma by 6 years of age. Farm
home-like microbiota showed a protective effect, as seen in the GABRIELA study [32]. The researchers
concluded that the composition patterns were more specific than bacteria population richness.
Preschool wheeze, which affects one in three children before the age of 3 years, remains a conundrum [34].
It remains unclear whether preschool children whose wheeze transitions in to school age asthma have the
same pathological entity, or are at risk of developing a separate pathological condition. Even in asthma in
school age children, diagnostic uncertainty is common suggesting a marked degree of heterogeneity in
underlying pathology [35]. Typical diagnostic tests include spirometry, exhaled nitric oxide (FeNO) and
atopy investigations. FeNO is a biomarker of airway inflammation which can be useful in the diagnosis and
monitoring of asthma. However, there is limited longitudinal data on FeNO trajectories. ECKEL et al. [36]
proposed that serial measurements of FeNO may have clinical applications. They analysed a cohort of
non-asthmatic children from the Southern California Children’s Health Study. Baseline FeNO had the
highest importance in determining FeNO trajectories. Whilst trajectories for all children are heterogeneous,
healthy children tend to follow their own course throughout childhood. The researchers confirmed
FeNO increases with age and height in healthy children, and that serial FeNO measurements have clinical
uses. Another set of compounds in breath that may provide new insights are volatile organic compounds
(VOCs) [37]. The “electronic nose” (eNose) uses exhaled VOCs to identify diseases [38], but studies on its
use in children are limited. BANNIER et al. [39] examined the feasibility and diagnostic accuracy of eNose in
children with asthma, CF and in healthy controls. 55 participants aged 5–20 years underwent eNose breath
sampling. With 98% successful measurements, the device was easy to use, provided high accuracy in
discriminating CF from asthma and healthy controls, and modest accuracy in distinguishing asthma from
healthy controls.
Whilst asthma treatments for mild-to-moderate asthma are well established, delivery of drug to the lower
airway and adherence in children remain problematic. Valve holding chambers (VHCs) enhance drug
delivery and eliminate coordination of actuation and inhalation. Commercially available VHCs have
different volumes, aerodynamics and mechanisms, but they are used interchangeably, assuming equal
efficacy. CSONKA et al. [40] assessed drug delivery with various VHCs while simulating different breathing
patterns (combinations of respiratory rate and tidal volume). There were marked dose delivery differences
between VHCs, though the differences remain constant for different breathing patterns. These researchers
stressed the importance of developing guidelines on what inhaler/VHC combination to use for what
age group.
In severe asthma, oxygen therapy is often used, but administration methods vary widely (e.g. temperature
and humidity). COMPTON et al. [41] compared the outcomes of children randomised to standard oxygen,
humidified oxygen or warmed humidified oxygen. Surprisingly, warmed humidified oxygen was poorly
tolerated and associated with treatment escalation. Taking into account these were pilot data, the authors
encouraged larger studies to standardise practice.
Insights into respiratory disease from epidemiological studies
Several studies using epidemiological approaches in clinical and population-based research were presented
at the Congress, focusing mostly on asthma and childhood wheeze but also on other paediatric respiratory
disorders such as primary ciliary dyskinesia. Research on pre-natal and post-natal early life factors and
their influence on later respiratory disease was the main theme of an oral session on “Recent insights in
childhood asthma and wheezing”. Pre-natal paracetamol exposure has been positively associated with
asthma development but not all studies have been consistent [42, 43]. BREW et al. [44] investigated the
association between analgesic use in pregnancy and childhood asthma by using family design methods to
assess possible confounding. Studies using sibling comparisons, where the mother took analgesic in one
pregnancy and not in the other, allow to control for genetic factors, extrinsic confounding and partially for
intrinsic confounding. The study population included 492999 mother–child pairs identified from Swedish
national registries. Analgesic use during pregnancy was identified from prescription data for paracetamol,
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anti-migraine drugs and codeine. Childhood asthma was assessed at ages 2, 3 and 4 years based on asthma
diagnosis and use of asthma medication [45]. All pre-natal analgesic use was associated with increased risk
of childhood asthma at all ages; however, the siblings comparison found no association between pre-natal
analgesic use and childhood asthma, suggesting that there might be possible confounding related to the
maternal factors. DAI et al. [46] investigated another aspect of analgesic use, studying the association
between paracetamol during infancy and risk of asthma in adolescents using data from the
Method-Melbourne Atopy Cohort Study [47]. After adjusting for frequency of early respiratory infections,
paracetamol use during the first 2 years of life was not associated with wheeze or lower lung function at
18 years of age. However, the study found an increased risk for lower lung function in adolescents with
GSTM1 null genotypes and GSTP1 Ile/Ile genotypes indicating that extensive use of paracetamol in children
susceptible to oxidative stress might be linked to long-term respiratory outcomes. KOTECHA et al. [48]
presented data from the Millennium Cohort Study [49] to identify wheezing phenotypes using machine
learning to estimate different latent class models. Recent wheeze was greater in the preterm-born group at
ages 3, 5, 7 and 11 years and four wheezing phenotypes were found, which were similar for both groups: 1)
no/infrequent wheeze; 2) early wheeze which disappeared in later years; 3) persistent wheeze throughout the
study period; and 4) late wheeze which appeared later in childhood. Preterm infants were more likely to
have early or persistent wheeze. The study showed similar early life risk factors for both preterm and
term-born children (e.g. atopy, antenatal maternal smoking, no breastfeeding and male sex) but their effect
was stronger in preterm children. CASAS et al. [50] focused on early growth patterns which have been
implicated to childhood asthma and lung function [51, 52], using repeated growth measurements for the
first 3 years of life of 4435 children from the Generation R study [53]. They used detailed individual growth
trajectories to assess the association of peak height and weight growth velocity, body mass index and age at
adiposity peak with lung function and reported asthma at age 10 years [50]. Greater peak weight velocity
and greater body mass index at adiposity peak were associated with a disproportionate increase in forced
vital capacity (FVC) compared to forced expiratory volume in 1 s (FEV1), leading to smaller airways in
relation to lung capacity. Animal and in vitro studies showed an effect of vitamin D on lung and immune
system development but there is little data from human studies [54, 55]. Using data from the Generation R
study, MENSINK-BOUT et al. [56] examined the association of 25-hydroxyvitamin D (25(OH)D) blood
concentration in mid-gestation and at birth with asthma and allergy outcomes at age 10 years. They found
that higher levels of 25(OH)D mid gestation were associated with a higher risk of inhalant allergen
sensitisation at school age, partially explained by the child’s 25(OH)D levels. All studies highlighted the
importance of cohort studies and the use of appropriate methods to clarify possible associations of early life
factors with respiratory outcomes in childhood.
Paediatric respiratory infections: translational and clinical perspectives
Several of the Congress sessions addressed paediatric respiratory infections, and excellent abstracts were
presented in this area encompassing epidemiological, translational and clinical research studies. AN et al. [57]
assessed whether induced sputum was an alternative to bronchial fluid to investigate the lower airway
microbiota. In a small sample of 12 children undergoing elective ear, nose and throat procedures (six with
known asthma), the microbiota in induced sputum and bronchial samples were found to be different, with
the former closer to that of upper airway samples. The authors also found that a minority of bacterial DNA
in bronchial samples remained unclassified. These findings suggest that induced sputum is not a valid
surrogate for direct bronchial sampling to study the lower airway microbiota in all children.
POH et al. [58] reported on the interaction between non-typeable Haemophilus influenzae (NTHi) and
respiratory syncytial virus (RSV) in a model of primary airway epithelial cells growing at the air–liquid
interface. RSV infection enhanced the growth of NTHi, but the opposite was not the case. NTHi produced
a confluent biofilm over the whole epithelial surface of the culture well, likely preventing contact of RSV
with epithelial cells. In vivo, biofilms are not likely to form this barrier throughout the bronchial surface;
modifications to this experimental model may be required to further study the interaction between RSV
and NTHi.
The roles of RSV genotype and host-immune interactions were presented by PIERANGELI et al. [59], using
clinical and biomarker data from a single-centre study of 96 inpatient infants with bronchiolitis. The
authors measured viral load and interferon-stimulated genes (MxA and ISG56) in nasopharyngeal
aspirates across two time-periods. The NA1 genotype predominated between 2005 and 2012, followed by
the ON1 genotype until 2017. Reduced severity of illness across a range of clinical outcomes was found
during the latter period. The NA1 genotype was associated with a lower viral load, but increased
expression of MxA and ISG56. These results provide further mechanistic insight on host-agent interactions
in RSV bronchiolitis, which are particularly relevant given the pipeline of new antivirals currently
in development.
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Two abstracts presented data on the association of infant bronchiolitis and lung function measurements at
later age. CANGIANO et al. [60] assessed ventilation inhomogeneity using multiple breath washout
measurements at 5–6 years of age in a cross-sectional study. Children with a history of bronchiolitis
(n=29) had a higher LCI than age-matched healthy controls (n=15), but less than children with CF
(n=20). RIIKONEN et al. [61] reported on follow-up spirometry at 10–13 years of age from a matched cohort
study comparing children hospitalised with bronchiolitis before 6 months of age (n=89) and controls
(n=108). This group had previously reported reversible obstruction (with forced oscillometry) at age
5–7 years in this cohort [62]. Early-life bronchiolitis was associated with reduced FEV1 and FEV1/FVC
before and after bronchodilation, including after adjustment for maternal smoking and current asthma.
Findings from these studies suggest that changes in lung function after early-life bronchiolitis are seen at
preschool age, and there may be irreversible bronchial obstruction by early adolescence. Methodological
caveats in establishing the causal effect of bronchiolitis include the selection of controls and the fact that
pre-existing factors such as lung function at birth were unaccounted for.
UNGER et al. [63] aimed to address a gap in evidence regarding the role of capillary blood gas analysis in
management of bronchiolitis. In a single-centre retrospective observational study over two bronchiolitis
seasons, blood gas was performed in 158 out of 326 hospitalised infants, 98 in the emergency department.
Elevated carbon dioxide tension was associated with high-dependency or intensive care unit admission
(OR 2.8; 95% CI 1.2–6.6) and length of hospital stay. Future studies designed to reduce biases inherent to
this study design would help further elucidate the prognostic value of blood gas, which would be relevant
for both clinical practice and future intervention trials.
Finally, RUFFLES et al. [64] presented the 5-year outcomes of a large cohort of children with protracted
bacterial bronchitis that underwent bronchoscopy (n=130). A considerable proportion of children who
underwent computed tomography had bronchiectasis (11 out of 59) and 15.7% had recurrent disease (>3
episodes per year) by year 5. Interestingly, 45.9% had a diagnosis of asthma. While there may be limits to
the extrapolation of these results, identifying prognostic markers of future airways disease at the index of
protracted bacterial bronchitis episode would be useful.
CF: diagnosis, monitoring, microbiological aspects and new treatments
The ERS Congress addressed the significant advances that have been made in CF management in the past
decade [65].
The oral communication session focused on microbiological aspects and new treatments in CF. LINNANE
et al. [66] described a prospective case–control study on the lower airway microbiome in pre-school
children with CF. Data on 291 sequenced bronchoalveolar lavages from 50 controls and 106 CF patients
showed that CF lower airway microbiome is distinct from the non-CF microbiome, had lower diversity,
and different relative abundance at phylum, family and genus level.
BRINKAM et al. [67] studied the role of exhaled breath in the detection of Pseudomonas aeruginosa of CF
patients. They found that three out of 138 VOCs in the exhaled breath were consistently different in
P. aeruginosa infected versus non-infected patients.
This pilot study provided support for the use of exhaled VOC analysis for early detection of P. aeruginosa
infections in CF patients and therefore help with prompt treatment.
Another study on volatile metabolites in the breath by BAGHDASARYAN et al. [68] presented on distinct
volatile markers from CF pathogens with secondary electrospray ionisation high-resolution mass
spectrometry (SESI-HRMS). With this technique, unique sets of four to 12 volatile markers were found for
P. aeruginosa, H. influenzae, Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. Several
markers for P. aeruginosa, Burkholdia cepacia and Stenotrophomonas maltophilia were closely related.
STAHL et al. [69] presented the randomised, double-bind, controlled trial of preventive inhalation of
hypertonic saline in infants with CF (PRESIS) study. The aim of that study was to determine safety and
efficacy of preventive inhalation of 6% hypertonic saline versus 0.9% isotonic saline in 42 infants with CF.
They demonstrated that inhalation with hypertonic saline is safe in infants, with good adherence and it is
associated with a reduction in the LCI and a significant better body weight gain after 12 months when
compared to isotonic saline alone.
BUSH et al. [70] discussed targeting α-epithelial sodium channel (ENaC) with an epithelial RNAi trigger
delivery platform for the treatment of CF. This complex work aimed to evaluate the efficacy of the
Arrowhead Targeted RNAi Molecule technology to develop epithelial-targeted conjugates comprised of an
optimised RNAi trigger against ENaC paired with an epithelial targeting ligands to the epithelial integrin
αvβ6. They demonstrated that inhaled epithelial targeting ligands–αENaC RNAi trigger conjugates
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produce selective, durable, renal-sparing silencing of pulmonary αENaC expression. Moreover, improved
mucociliary clearance was observed in sheep 2 weeks after inhalation of aerosolised conjugate.
The second oral communication session focused on the new developments in diagnosis and monitoring
in CF.
JENSEN et al. [71] reported the effects of deviations in tidal breathing on multiple breath washout
measurements. Using a large retrospective dataset, the authors demonstrated that within the range of tidal
volumes observed, minor deviations from ideal tidal volume and sighs did not impact end-tidal nitrogen
concentration, and had only small effects on functional residual capacity and LCI that are unlikely to be
clinically relevant.
CIUCA et al. [72] evaluated the relationship between lung ultrasound score and lung function expressed by
LCI in a cohort of 42 children with CF. The authors found an important and statistically significant
correlation between lung damage evaluated by the lung ultrasound score and the LCI. Thus, they
speculated that lung ultrasound score might be used as a primary evaluation of CF lung damage.
NYILAS et al. [73] presented on the repeatability of ventilation and perfusion assessment by functional
magnetic resonance imaging (MRI) in children with CF. Pulmonary MRI techniques such as matrix pencil
decomposition allow for the evaluation of regional impairment of the regional fractional ventilation and
relative perfusion in patients with CF. However, the repeatability of matrix pencil-MRI outcomes in
children with CF is unknown. The authors demonstrated a good short-term repeatability, making this
technique promising for early detection of CF lung disease.
SMITH et al. [74] expanded the MRI theme further in their presentation on the effect of inhaled lung
volume on ventilation heterogeneity in CF using 3He MRI. In patients with CF, ventilation abnormalities
using hyperpolarised gas ventilation MRI are a very early sign of disease (more sensitive than LCI or
spirometry) but the relationship between tests of lung function and ventilation MRI has only been assessed
in mild CF disease. The authors demonstrated that there is a strong correlation between 3He MRI and the
LCI. Moreover, deep inspiration reduces, but does not always cause, ventilation abnormalities to disappear.
This has implications for scanning techniques.
HARDY et al. [75] presented the comparison between the 1-min sit-to-stand test and quadriceps strength in
patients with CF. The 1-min sit-to-stand test has the capacity to assess peripheral muscular strength and
endurance and has not been well evaluated in CF. The authors demonstrated that the 1-min sit-to-stand
test could be a good alternative to the dynamometer to estimate quadriceps strength in stable patients with
CF. Moreover, this test is easily realisable during routine visits and reproducible.
Finally, FROST et al. [76] discussed their work on the association between glycaemic variability indices and
pulmonary function decline. This was a retrospective analysis of 56 CF patients undergoing continuous
glucose monitoring. All measures of glycaemic variability showed inverse correlations with baseline FEV1,
though there was no clearly superior outcome measure of the different methods presented.
All presentations provoked interesting discussion from the audience, and show how research in the field of
CF is extremely lively and at the cutting edge of a number of different techniques.
Recent advances in PCD
PCD is a rare hereditary disorder, with disease-causative mutations reported in >39 genes to date and a
prevalence of approximately 1:10000 [77, 78].
Clinical predictive tools have been developed to guide referrals for diagnostic testing [79, 80]. Nasal nitric
oxide (nNO) is low in patients with PCD but can be normal in patients with specific mutations [81, 82].
Additionally, MARTHIN et al. [83] have recently shown that nasal nitric oxide decreases during respiratory
tract infections. The ultrastructure of motile cilia, which can be examined by transmission electron
microscopy, consists of nine microtubule doublets and central pair. The nodal cilia at the embryonic node
lack the central pair, resulting in a rotational movement that determines the left–right pattern of major
organs. Disruption of this flow can lead to situs inversus totalis in ∼50% of patients, with complete mirror
image of major organs or various combinations of laterality defects, the latter can be associated with
congenital heart disease. Ciliary biopsy for evaluation of cilia function through high-speed video
microscopy can show abnormal beat pattern; however, subtle abnormalities can be difficult to spot and
secondary defects due to infection are common [84].
Mutations in DNAH5 account for a 25% of all patients. Recent studies have expanded the understanding
of PCD genetics, with the discovery of genes that encode proteins located in the cytoplasm (i.e.
pre-assembly genes) [85] and mutations on X-linked genes (e.g. PIH1D3), where a single heterozygous
mutation can be disease-causative in men [86]. DAVIS et al. [87] reported worse respiratory phenotype in
https://doi.org/10.1183/23120541.00241-2018 7
PAEDIATRICS | R. NENNA ET AL.
patients with CCDC39 and CCDC40 and less severe phenotypes were described in some patients with
RSPH1 and CCDC103 mutations, highlighting the fact that PCD is a heterogeneous disease [77].
However, despite significant advances in PCD genetics, it remains a complex field, with approximately
25% of PCD patients not having an identified bi-allelic mutation in a known gene. New diagnostic
modalities include electron tomography and immunofluorescence. The ERS diagnostic guidelines and the
recently published American Thoracic Society guidelines provide important guidance on diagnostic testing
for PCD but there are significant differences between the two, reflecting different target audiences and
expertise [88, 89]. Hallmark transmission electron microscopy defects and bi-allelic (or X-linked)
mutations on a known PCD-causative gene confirms the diagnosis of PCD; however, combination testing
remains essential to exclude the diagnosis.
Clinical symptoms reported by patients vary with age [78]. Similarly, pathogen prevalence varies with age
and colonisation by P. aeruginosa associated with lower lung function [90]. Importantly, a recent
international study showed that lung function is similarly impaired in patients with PCD and CF [91].
The sperm flagella and the fimbriae of fallopian tubes exhibit a similar structure to respiratory cilia,
leading to fertility problems in men and women. Recently, a retrospective study with 85 PCD patients
reported over half of the women had children, 39% through spontaneous conception and 17% after
assisted fertility. Spontaneous conception was lower in men (24.5%) [92].
PCD management is currently based on two expert consensus reports [93, 94], largely extrapolated from CF
and non-CF bronchiectasis management as there are very few longitudinal studies in PCD. PAFF et al. [95]
reported no difference in quality of life between patients on hypertonic saline and isotonic saline in a
double-blind crossover randomised controlled trial. However, it was underpowered and the primary
outcome was not disease specific. Another randomised control trial is investigating the efficacy and safety of
azithromycin prophylaxis [96] and a crossover randomised controlled trial is evaluating the safety and
efficacy of VX-371 inhalation, an ENaC inhibitor. Smoking cessation, immunisation, physical activity,
airway clearance and antibiotics to treat exacerbations and eradication of P. aeruginosa are currently
indicated for the management of PCD patients, with other therapies such as hypertonic saline,
azithromycin prophylaxis and bronchodilators used on a case-by-case basis.
The breadth and depth of PCD research at the 2018 ERS Congress highlighted the need for international
collaboration to advance PCD research. Initiatives such as the international PCD Registry, the North
American PCD Registry and the iPCD cohort represent an important step towards standardised collection
of clinical and diagnostic data for this rare disease [78].
New ideas about respiratory and sleep physiology in children
WEBER et al. [97] presented their work around validation of the Sleep Clinical Record Protocol which was
created by an Italian group. The tool was tested in 51 Brazilian children with obstructive sleep disorders
and tonsillar hypertrophy. There was no difficulty in the use of the tool in different groups of patients.
The sensitivity was 0.89 and specificity was 0.19, compared to polysomnography data. The quite low
specificity could be associated with the sample selection bias (tested mainly in patients requiring
adenotonsillectomy). Validation of the tool in a more representative group of patients will follow.
Short lingual frenulum at birth has been associated with increased obstructive sleep apnoea in school age
years. This observation was confirmed in a retrospective study of 547 children of mean age 9.6 years
presented by EVANGELISTI et al. [98]. 140 out of 547 children with obstructive sleep apnoea had short
frenulum and, in these children, lower tongue strength was measured.
No studies have specifically clarified the need for carbon dioxide monitoring in paediatric sleep disordered
breathing assessment. TRUCCIO et al. [99] attempted to determine how often overnight carbon dioxide
monitoring could change management of patients when added to cardiorespiratory polygraphy data. This
was a retrospective study of 2 years using data on paediatric patients referred for investigation of sleep
disturbed breathing. In 107 (82%) out of 130 otherwise healthy children, obstructive sleep apnoea was
diagnosed. Carbon dioxide did not change management when added to cardiorespiratory polygraphy.
However, in 20 out of 383 children with pre-existing medical conditions there were detectable carbon
dioxide changes that guided management. Therefore, overnight carbon dioxide monitoring was not proven
to be necessary for the diagnosis and management of obstructive sleep apnoea in otherwise healthy
children but was crucial for the management of patients with comorbidities.
A population survey study in the UK, analysed by a Scottish team [100], looked at best management
approaches in patients with Robin sequence. From analysis of 153 cases, evenly spread across the UK, it
was shown that a non-surgical approach in the management of upper airway obstruction, involving use of
nasopharyngeal airways, can be equally effective compared to a surgical approach.
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Although common thinking would associate positively the in utero tobacco exposure with lung deficits,
there are controversial data deriving from birth cohort studies. Glutathione s-transferase is an enzyme
involved in detoxification and its active genotype has been associated with better lung function in infants.
OWENS et al. [101] from Australia presented their birth cohort study relating lung function in early life
with in utero triggers, more specifically tobacco exposure. They identified that risk for development of
significant lung deficits is higher in infants with maternal tobacco exposure lacking the active genotype of
this enzyme.
Practice varies regarding assessment of bronchodilator response in children with normal baseline
spirometry and this is an important question to answer since nearly one-third of asthmatic children have
normal baseline spirometry. BEYDON et al. [102] conducted a retrospective study showing that children
with negative bronchodilator responses are often prescribed inhaled steroids and that normal baseline
spirometry but abnormal main airway resistance is correlated with positive bronchodilator responses.
Therefore, basing diagnosis and management on baseline spirometry needs a revisit.
VERHEGGEN et al. [9, 103] from Australia presented their work around validation of the hypoxia challenge
test in preterm infants. The tool was validated in 30 preterm and 24 term, predominantly male, infants
taking in total 54 domestic flights in Australia lasting from 1.1 to 5.5 h. Parents were holding portable
oxymeters and were recording behaviour (including sleep or awake). The test failed to predict oxygen
requirement in flight. Factors associated with both the infant (variation between flights) and physiological
changes (peripheral oxygenation, changes in altitude) could potentially explain this outcome.
As discussed above, predictive markers for short- and long-term respiratory morbidity in premature
infants would be clinically useful. In the area of respiratory physiology, USEMANN et al. [104] from
Switzerland reported data on whether intraindividual variability of ventilation inhomogeneity and
capnographic parameters is associated with subsequent respiratory morbidity and could potentially
enhance the predictive power of BPD severity classification. Using a prospective birth cohort study of 133
preterm infants the researchers found that preterm infants who require rehospitalisation due to respiratory
complications during the first year of life have a lower variability of several tidal breathing parameters
shortly after birth and the BPD severity score had very low predictive power while by adding tidal volume
or carbon dioxide variability to the predictive model, there were small improvement in performance.
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